The leadership behaviors needed to implement clinical genomics at scale: a qualitative study by Best, S et al.
The leadership behaviors needed to implement clinical
genomics at scale: a qualitative study
Stephanie Best, PhD, MSc 1,2, Zornitza Stark, BM BCh, DM2, Helen Brown, PhD, MSc3,4,
Janet C. Long, PhD, MN1, Kushani Hewage, MSc2,5, Clara Gaff, PhD, FHGSA3,5,
Jeffrey Braithwaite, PhD, FAHMS1 and Natalie Taylor, PhD6,7
Purpose: To investigate leadership in clinical genomics and
identify likely implications of different leadership approaches for
future implementation of clinical genomics.
Methods: We undertook 37 interviews in a cross-sectional
qualitative study examining implementation of clinical genomics
in Australia. Participants were either nongenetic medical specialists
working with genomic initiatives (e.g., immunologists, nephrolo-
gists) or working at a service/organizational level (e.g., department
heads, chief medical officers). We identified participants as genomic
migrants (long-established practitioners) and genomic natives (those
medical specialists coming into independent practice with genomic
technology in situ). Data were analyzed deductively with reference
to leadership approach.
Results: Leadership approaches were often blended or reported to
iteratively support development of another. There was concern at both
the absence or the excess of entrepreneurial leadership (i.e., risk-taking).
Conclusion: Entrepreneurial leadership is needed to promote
innovativeness, risk-taking, and proactivity, essential in these early
stages of clinical genomics. Shared decision-making is required from
a wide range of clinicians, calling for both clinical and distributed
leadership. Sharing leadership, and the potential loss of positional
status from formal senior positions, may prove challenging to
genomics “migrants,” who are essential for nurturing genomic
“natives.” Clinicians will need support from their organizations and
professional bodies to manage the transition.
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020-0818-1
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INTRODUCTION
Emerging complex medical technologies offer the promise
of improved health outcomes, though they rarely integrate
readily with pre-existing infrastructure and knowledge.1
The resultant whole of system changes envisaged for health
care are likely to be disruptive to the extant health-care
delivery environment.2 Genomic testing is an example of a
new technology that holds the potential to provide faster,
more reliable diagnosis and drive personalized treatment for
many. However, providing results that are clinically mean-
ingful requires not only substantial investment in the
complex technology but also multiple professionals to
engage throughout the system and across the sociotechnical
divide. Engaging medical practitioners is essential to
delivering sustained change.3 Yet, many medical practi-
tioners feel underprepared for clinical genomics4,5 and
carefully considered leadership approaches will be required
to facilitate the adoption of this new complex technology.
Despite being outdated, the traditional leadership model in
medicine is hierarchical6 with those in senior roles utilizing
“top down” approaches of leadership arising from their
positional power and perceived expertise.7 Genomic med-
icine usurps this convention by providing opportunities for
early career medical practitioners to lead different areas of
clinical genomics delivery (e.g., in clinical genetics,
nephrology, neurology, immunology). This raises interest-
ing parallels with digital technologies: just as we talk about
digital natives (i.e., those born in the digital era) and
migrants (i.e., those who came to digital technologies later
in their life)8 clinical genomics too has natives and
migrants. Genomic natives are coming into independent
medical practice with genomic technology already in situ.
This is not to suggest they are experts or have assumed
comfort in the field, but this phenomenon holds the
potential to pose a challenge to migrants who see their
status quo changing.8 These challenges relate to Prensky’s8
concepts of “legacy”, for example, traditional concepts
around clinical practice and team management, and
“future”, for example, imagining how medicine will be
practised in the medium to longer term. Perhaps
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unsurprisingly, this shift can be challenging for more
established practitioners/genomic migrants who are
entrenched in historic cultures of leadership.
Leadership
The Australian health leadership framework describe leaders as
those who “engage with others to influence health and well-
being and the quality of care for birth, illness and the end of
life”.9 Leadership is a controversial and complex concept and
while there is no consensus definition of leadership there are
common themes including vision,10 clarity of goals,11 and
influencing others.12 Leadership theories are plentiful13 and
have progressed from an early focus on the leaders’ personality
(trait theory14) to the followers’ behavior (situational leader-
ship15) to now recognizing that context and leadership are
interwoven.16,17 Leadership approaches omnipresent in health
care are senior leadership, clinical leadership, and distributed
leadership (Fig. 1). Senior leadership, as outlined above, derives
power from the position held in the organization, or through
the medical hierarchy an assumption of an expert role.6,7 By
contrast, clinical leadership calls for health-care professionals to
draw on their clinical experience and knowledge to provide
leadership focused on patient care. Edmonstone18 notes clinical
leaders tend to (1) use persuasion, rather than hierarchical
power; (2) prefer evidence-based and planned change in
consultation with colleagues; and (3) use reflective practice
rather than a technical–rational approach. Distributed leader-
ship, where the responsibility for day-to-day decision-making
and action is shared, has risen in prominence in health and
social care as a means to promote formal and informal leaders
working together to realize an organization's aspirations.19
Distributed (also known as shared or collective) leadership can
be defined as “a collective social process emerging through the
interactions of multiple actors”20 whereby leadership comes
from all team members,19 where roles are fluid, and participants
promote continual improvement.21 What these theoretical
approaches do not take into consideration is leadership in the
context of the uptake of new, and potentially challenging,
complex technologies. We posit that entrepreneurial leadership
can fill this void and complement senior, clinical, and
distributed leadership as a means to deliver complex emerging
clinical technologies such as genomics. Entrepreneurial leader-
ship has been defined as “influencing and directing the
performance of group members toward the achievement of
organizational goals that involve recognizing and exploiting
entrepreneurial opportunities”,22 and promotes innovativeness,
risk-taking, and proactivity.23 This definition suggests open
mindedness is needed to see emerging complex technologies
implemented in health care.
Literature exploring leadership in genomics is sparse with
limited original research studies evident. A large focus is
placed on education,24 and the need to upskill the nongenetic
workforce, highlighting the potential role many professions
may play (e.g., social workers,25 physiotherapists26). Remark-
ably, medical practitioners are the focus of very few studies
examining leadership in genomics. Using the Geisinger
Health System and Kaiser Permanente as examples, Reinke27
identifies the need for leadership to encourage medical
practitioners to make the move from genetics to genomics,
noting that without this engagement, implementation will not
succeed. Furthermore, Lieu et al.28 reported oncologists’
genomic practices were influenced by leadership, placing this
variable even ahead of funding, and argued for the need to
leverage this to facilitate implementation.
Clinical Leadership
Senior Leadership
Distributed Leadership
Entrepreneurial Leadership
Clinicians led by clinicians
Leadership based on hierarchy, position or expertise Comfortable with risk, innovation and values pro-activity
A shared approach, no one expert
Fig. 1 Four leadership approaches.
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Aims
We sought to bridge theory and action by exploring the extent
to which different leadership styles are employed in clinical
genomics practice in Australia, a country progressing rapidly
with genomics implementation. In particular, we address the
following research questions: (1) Do medical practitioners
implementing clinical genomics directly or indirectly engage
with clinical, distributed, senior and/or entrepreneurial
leadership? and (2) What are the implications of different
leadership approaches for the implementation of clinical
genomics in the future?
MATERIALS AND METHODS
Context
A large number of national genomic medicine initiatives have
been funded worldwide to accelerate the implementation of
genomics into clinical practice.29 In Australia, the Australian
Genomics Health Alliance is a national collaborative research
partnership that aims to pilot approaches and develop
evidence to inform national integration of genomics into
mainstream health care.30 In addition, several state-based
programs have been funded, including the Melbourne
Genomics Health Alliance, which is working to implement
genomics in Victoria.2 Alongside the “top down” strategy,
each of these health alliances promote a “bottom up”
approach to clinical genomics with clinicians leading the
delivery of the genomic medicine projects.
Research design
This study was part of a larger implementation research
program investigating the barriers and enablers to the use of
genomics in clinical practice and devising an implementation
strategy for new adopters across Australia. An overview is
provided here, and methodological detail, including interview
schedule content, can be found elsewhere.31 To gather data on
leadership, a deductive qualitative approach was adopted
using secondary analysis of semistructured interviews.
Participants and recruitment
To examine perceptions of implementing clinical genomics, we
purposively selected two participant groups via Australian
Genomics and Melbourne Genomics: (1) service level decision
makers, for an organizational level perspective, and (2)
nongenetic medical specialists, for a frontline clinical view. An
expert resource group, including clinicians and researchers each
with relevant academic and/or contextual knowledge, proposed
a total of 62 people who were then invited to interview by email
(S.B.) with two follow-up reminder emails if required.
Data collection tools and procedure
We designed two theoretically informed interview schedules
to examine the barriers and enablers to implementation of
genomics in clinical practice. For the medical specialist
interviews, we used the Theoretical Domains Framework32 to
identify individual practitioner perceptions along the clinical
patient pathway (ensuring appropriate patients are selected
for genomic testing, requesting testing and interpreting the
data, providing results to patients, and finally mainstreaming
genomic testing). For the service level decision makers, we
used Spoth et al.’s33 Translation Science to Population Impact
framework to gather data along the adoption timeline
(preadoption, adoption, implementation, and sustainability).
We shared the study concept with the Melbourne Genomics
Consumer Advisory Board (CAG) to gain their views on
patient-relevant questions to ask at interview. The CAG was
also asked for their views on the findings.
Ethical review was provided by Melbourne Health Human
Research Ethics Committee (HREC/13/MH/326) and govern-
ance approval was provided by Austin Health; Australian
Genomics Health Alliance; Monash Health; Peter MacCallum
Cancer Centre; the Royal Childrens Hospital, Melbourne; and
the Royal Melbourne Hospital. Following provision of
participant information and an opportunity to ask questions,
interviewees were asked to provide verbal consent for
participation.
For consistency and reliability, one highly experienced
qualitative researcher conducted all the interviews (S.B.).
Interviews were conducted face-to-face where possible (n=
31) with the remaining interviews (n= 6) undertaken by
videoconference. On average, interviews lasted 60 minutes. All
were audio recorded with participant consent, fully tran-
scribed, and managed using NVivo.34 Each transcript was de-
identified, using a unique identifier (MP 1, 2… for clinicians
and SL1, 2… for service level decision makers; GM for
genomic migrants [i.e., long-established medical practi-
tioners]; and GN for genomic natives [i.e., medical practi-
tioners coming into independent practice with genomic
technology in situ]). There are no established criteria for
designating genomic migrants and natives and so two
experienced coauthors (S.B. and Z.S.) independently assessed
all the participants invited to interview to determine if they
were genomic natives (i.e., had come to independent medical
practice with genomic technology in situ for them) or were
genomic migrants (i.e., longer-standing members of the
medical community for whom genomics had been introduced
after they had become an independent practitioner). There
were no disagreements between assessors.
Data analysis
First, using broad leadership concepts of vision, clarity,
influencing others, taking responsibility, and including any
direct reference to leadership, we assessed the data for any
mention of leadership. Typically, these data reflected
participants' own experiences, perceptions, and expectations
of leadership from others while implementing genomics in the
clinical setting, but on occasion participants also discussed
their own need and/or leadership style. Then, using a
deductive approach we interrogated the interview data and
identified the key components of leadership, in the context of
clinical genomics, looking for evidence of (1) clinical leader-
ship (i.e., the tendency to use persuasion, rather than
hierarchical power; evidence-based change; and/or use of
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reflective practice); (2) distributed leadership (i.e., the
propensity for responsibility to be diffused, and for formal
and informal leaders to work together); (3) senior leadership
(i.e., power through hierarchy); and (4) entrepreneurial
leadership (i.e., the tendency to support innovativeness,
risk-taking, and proactivity). See Supplementary file for
further details. Transcripts were coded independently by
two experienced qualitative researchers (S.B. and H.B.) and
discrepancies in coding, for example where there was the
potential for overlapping themes, were resolved through
discussion to resolve uncertainty. Where needed, a third
researcher (N.T.) assessed the transcripts as arbiter and gave a
final decision.
RESULTS
First, we report on the demographics of the interviewees, then
we present findings related to the leadership concepts stated
above, including the merging of leadership approaches.
Finally, we provide evidence where an absence or excess of
entrepreneurial leadership was reported.
Demographics of interviewees
All who responded to the email invitation were interviewed
(n= 37), representing 11 organizations. Participant demo-
graphics are presented in Table 1. The majority of service level
decision makers were genomic migrants (n= 14/21) while the
mainstay of the nongenetic medical specialists were genomic
natives (n= 11/16). A large proportion of participants were
based in Victoria possibly reflecting both the scale of support
the Melbourne Genomics Health Alliance has received to date
and Melbourne as the geographic base for Australian
Genomics.
Specific leadership approaches
Examples of all four leadership approaches found in the
interview data are presented here, including data where
participants described combinations or a merging of
approaches. There was no marked disparity in responses
between nongenetic medical practitioners (MP) or service
level decision makers (SL); however, there was a difference
between MP genomic migrants and natives. MP genomic
natives were more likely to discuss leadership with relatively
few comments coming from MP genomic migrants. Only MP
natives (and not MP migrants) referenced entrepreneurial
leadership.
Table 2 provides exemplar quotes demonstrating the
concepts for (1) clinical leadership, e.g., the use of
nonhierarchical power or the importance of clinical cham-
pions; (2) distributed leadership, e.g., the need for collabora-
tion ensuring formal and informal leaders work alongside
each other; (3) senior leadership, e.g., engagement from
people in senior management roles in the organization with
the influence of senior leaders and the top down buy-in seen
as essential to complement the activities of clinical leaders in
implementing genomics; and (4) entrepreneurial leadership,
e.g., proactivity and risk-taking.
There were cases where participants reported one leader-
ship approach merging into another; for example, entrepre-
neurial with distributed leadership, with the initial proactivity
leadership resulting in collaborative work:
“There was clearly very little or no implementation or
translational research going on and so at that time we were
talking a lot about how do we get something which is so
clearly in the direction we’re going… then we had a few
good people to lead it out and say actually, ‘You know,
what we need is a partnership that just simply says we’ve
just got to start.” SL2 GM
There were also examples of senior leadership blending with
entrepreneurial leadership, with the senior figure exhibiting
the risk-taking behavior of entrepreneurial leadership:
Table 1 Demographic profile of interviewees.
Service level decision makers (SL) Nongenetic medical practitioners (MP)
Roles represented N Native Migrant Roles represented N Native Migrant
Attended (invited) 21 (35) Attended (invited) 16 (27)
Clinical geneticist 10 4 6 Neurology 4 2 2
Laboratory lead 4 2 2 Cardiology 1 1
Clinical project lead 2 1 1 Nephrology 6 5 1
Service lead/managera 5 5 Immunology 2 2
Oncology 3 3
Subtotal 7 14 11 5
Breakdown by geography
Victoria 11 15
Queensland 5 1
Western Australia 3 0
South Australia 1 0
New South Wales 1 0
a4 had clinical backgrounds.
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“…it was really the chief medical officer [who] really
recognized that this is just a huge part of where medicine is
going; it’s not just genetics… It’s going to touch all areas of
medicine and that not being part of it when we were a
genetics hub, for the state, would have been a bad
error.” SL7 GM
In addition, the need for a range of leadership approaches at
multiple levels was noted, here suggesting senior with clinical
leadership:
“Responsibility [for implementation of genomics] lies at
many different levels so you need high level leadership on
this.… There needs to be a sustained effort in that regard
and then it comes down to local leadership.” SL1 GN
Expanding and narrowing boundaries for entrepreneurial
leadership
Concern was expressed when there was an absence of
entrepreneurial leadership; for example, the lack of risk-
taking associated with decisions not to invest funding now,
given that benefits will not be realized for many years:
“It is a matter of somebody saying we’ll invest now and
we’re expecting the outcome in 10, 20 years. Which is a
brave... it is not the way cycles are done.” SL13 GM
Here, the interviewee is calling for risk-taking with
funding to reap rewards longer term. Contrary to perceptions
of a lack of entrepreneurial leadership, participants also
identified concerns when entrepreneurial leadership goes too
far:
“This is such a change of direction for clinical geneticists,
and not everybody has the same evangelism that we do,
and maybe the evangelism is a bit off-putting in a way.
Maybe it’s a bit too gung-ho, I don’t know, or needed to
appeal to their egos.” SL3 GM
This is a moment of clarity. Enthusiasm for the proactivity
captured in entrepreneurial leadership, demonstrated in this
quote, was seen to pose the risk of others being discouraged
from engaging.
In summary, all four leadership approaches were found
within the interview data. The leadership approaches were not
always mobilized in isolation and could either be blended, or
iteratively supported the development of other styles or roles.
Participants noted there was a perceived lack of risk-taking at
times suggesting an absence of entrepreneurial leadership.
However, counter to this was concern of the impact of being
“gung-ho” and overly proactive in furthering the genomics
agenda.
DISCUSSION
Findings from this study indicate entrepreneurial leadership
has a part to play alongside clinical and distributed leadership
when implementing clinical genomics. Although clinical and
distributed leadership have an essential role in day-to-day
clinical practice, the openness to innovation, risk, and
enthusiasm for activity or “just doing it” (SL4 GM) of those
embracing entrepreneurial leadership can encourage
Table 2 Exemplar quotes for clinical, distributed, senior, and entrepreneurial leadership. See Supplementary table for
additional quotes.
Clinical Distributed
“It can’t be imposed by the board. Something like genomics needs to be
owned by the clinicians for it to succeed. So, you need to have people who
are going to drive it.” SL5 GM
“I think [genomics] should be led by our clinical geneticists, with the
specialties…. I think having a genomics champion in a way that helps
other—gets other people onto to the lifeboat with us, I think is
good.” MP5 GN
“So, it’s—I think everyone having their area of responsibility, so people have
to have purpose, they have to feel that they own something.” SL11 GN
“My aim would be that this is something that any member of my team can
be part of. And so I might do one in three clinics, for example and my
colleagues would do the other two of three. Because then we all learn and
we all expand our knowledge base. I think for a junior consultant, they will
be more aware of genetics than I ever was as a junior consultant.”
MP15 GM
Senior Entrepreneurial
“I think the main driver is probably the unit head, and I think they probably
have a lot to do with every organization, so if you’ve got someone who is
quite motivated, on top, then there’ll be some kind of support change and
then sort of being encouraging of what happens around that.” MP14 GN
“We just have a particularly visionary chief executive here who’s very good
at pushing ahead on all sorts of fronts. It’s person-dependent in that
respect. Because if you’ve got a good CEO, things are happening.”
SL13 GM
“[Organizations] are very flexible, agile. I don’t think there’s one thing that
we’re good at and I mean, the critical issue is actually doing it, and being
prepared to learn as you go and adapt processes.” SL4 GM
“[We need] a militant arm that’s designed or whatever, at least in the early
stages of establishment to do the advocacy.” MP16 GN
“I’ve been involved with it from the start I guess at the start particularly
when there wasn’t very much clarity around because—partly because
nobody really knew what the outcomes were going to be or what we were
working towards it was kind of a toe in the water.” SL1 GN
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participation with new complex technologies not envisaged by
other leadership approaches.
Do medical practitioners implementing clinical genomics
directly or indirectly engage with clinical, distributed,
senior, and/or entrepreneurial leadership?
Clinical leadership is identified as essential: as autonomous
practitioners, the implementation of any new clinical
technology is destined to fail without securing engagement
from clinicians.35 Senior leadership, to support clinicians, was
also valued by genomic natives and migrants at both clinical
and organizational levels. The need to be comfortable with
taking risks, to be prepared to “put a toe in the water” (SL1
GN) and the significance of promoting a proactivity (and in
some cases “militant” [MP16 GN]) agenda was highlighted
demonstrating the presence of entrepreneurial leadership.
Leadership styles were not always seen in isolation, suggesting
no single approach will be effective, or even appropriate, on
its own. Instead of generating a new theoretical approach,
careful consideration to identify the best elements for use at
the most appropriate times by the relevant people may be of
value. Thus, contingency leadership—adopting the style and
approach suited to the specific purpose and task at hand—
looms as key to future progress with the implementation of
genomic medicine.
What are the implications of different leadership
approaches for the implementation of clinical genomics in
the future?
The results highlighted that clinical leadership in isolation is
unlikely to result in the sustainable implementation of clinical
genomics and “responsibility lies at multiple levels” (SL1 GN).
Although essential, the “bottom up” approach from clinicians
without senior leadership may result in small pockets of
excellence (or activity) leading to uneven adoption, patchy
progress, and unsustainable service provision.36
Distributed leadership calls for an openness to contribu-
tions from the wider clinical team,20 including genomic
natives, and leveling out of hierarchy,19 which is likely to
lead to disruption of traditional medical structures and—in
the context of genomics particularly, may subsequently
begin to challenge the traditional “elite expert senior
consultant” model of senior doctors. Sharing knowledge
can result in a loss of “expert power”,37 which is challenging
for the medical profession.38 If genomic natives arrive with
new genomic skills gained and developed through sharing
among the native cohorts there is a risk genomic migrants
may feel slighted. Due to the enormity of data in clinical
genomics, new approaches will be required for knowledge
gathering, use, and integration (i.e., where to access knowl-
edge rather than knowing all the answers). As genomic
natives develop, they will need the support of more
longstanding clinicians (i.e., genomic migrants) to help
them navigate the health-care system infrastructure. There
is potential here that the natives may eventually supersede
the knowledge and skills of the migrants. This presents
the challenge of not “eating our young”39 and ensuring
genomic natives are nurtured.
Entrepreneurial leadership was not reported as a panacea
for progress. Indeed, concern was expressed when it went
unchecked, for example with genomic “evangelism” (SL3
GM). However, the absence of risk-taking, proactivity, and
innovation is likely to hinder the implementation of clinical
genomics and there is a need to promote a readiness to
innovate and preparedness to learn from failure.40
As to limitations, this study was undertaken in one country
with a specific health-care delivery infrastructure. Implemen-
tation strategies for genomics vary internationally so caution
is warranted in interpreting these findings elsewhere. The
interview schedule was designed to gather views about
implementation of genomics into the clinical setting and as
such could limit the findings on leadership. Nonetheless, the
fact that leadership was not the focus of the interviews, but
strongly emerged from the data is an important finding in and
of itself demonstrating it is at the forefront of clinicians’
minds. Using this opportunity to analyze the data and start to
bridge the knowledge/practice gap has highlighted a number
of needs relating to the implementation of genomics, as well
as new avenues for research. Our future research will look to
specifically investigate leadership in clinical genomics across
multiple health settings.
All in all, we have started to disentangle some of the early
conversations in an emerging field to promote debate on
identifying and adopting appropriate leadership approaches
in clinical genomics. It raises many more questions and
requires further study. We are now aware of some of the
implications associated with these different leadership
approaches. As such, new questions arise that will benefit
from future research: how can we leverage the advantages of
each approach? Are there more or less appropriate times or
circumstances in which to apply any one style or role along
the genomics implementation pipeline? Are different
approaches required for natives versus migrants? Our aim
was to bridge leadership literature and practice in clinical
genomics. Our findings demonstrate clear recognition of all
four leadership approaches and appreciate that, despite the
autonomy of medical practitioners, there is a need for buy-in
from senior leaders (migrants or natives). The “bottom up”
approach of clinical leadership, prominent in Australia, in
isolation, is unlikely to lead to sustainable implementation.
The complexity of clinical genomics demands team decision-
making and distributed leadership will be challenging for
some. As a result of this shift in leadership approaches,
support from professional bodies and medical opinion leaders
will be required for genomic migrants to be comfortable in the
fast moving era of genomics and also to ensure they can
nurture the developing genomic natives.
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